remdesivir

What a letdown.

Six weeks of endless speculation, guessing, second-guessing, ups, and downs about whether the world would have its first effective coronavirus drug has been exhausting. I see the damn molecule in my sleep.

First, we do not know whether remdesivir has failed. Not by a long shot. The leaked draft document of a trial in China may or may not be real.

The world got a taste, albeit, a premature taste, of some bad news this afternoon.

Gilead Science is the Tom Brady of the antiviral research world. No other company even comes close.

Stat News just broke a story that has been picked up by the wider press and has generated quite a bit of

It is rare to find a mention of Giliead's remdesivir, arguably the most promising drug in the fight against coronavirus, without also hearing that it failed miserably in fighting Ebola.

Within the coming weeks, we should be starting to get a picture of whether remdesivir will be a savior to the world, just another failed drug, or something in between.

Q: What's worse than being in the middle of a coronavirus pandemic? A: Being in the middle of a coronavirus pandemic and having to read about synthetic organic chemistry. Yet, here we are, so pay attention.

There is now a potentially important change in the pharmaceutical landscape of anti-coronavirus drugs.